Celyad Oncology (Celyad Oncology) FCF Margin % : 0.00% (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Celyad Oncology FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Celyad Oncology's Free Cash Flow for the three months ended in Jun. 2023 was $0.00 Mil. Celyad Oncology's Revenue for the three months ended in Jun. 2023 was $0.00 Mil. Therefore, Celyad Oncology's FCF Margin % for the quarter that ended in Jun. 2023 was 0.00%.

As of today, Celyad Oncology's current FCF Yield % is -220.48%.

The historical rank and industry rank for Celyad Oncology's FCF Margin % or its related term are showing as below:

During the past 12 years, the highest FCF Margin % of Celyad Oncology was -264.42%. The lowest was -938033.33%. And the median was -12365.75%.

CYADY's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -144
* Ranked among companies with meaningful FCF Margin % only.

Celyad Oncology FCF Margin % Historical Data

The historical data trend for Celyad Oncology's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology FCF Margin % Chart

Celyad Oncology Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

-931.38

-457,528.57

-567,400.00

Celyad Oncology Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Celyad Oncology's FCF Margin %

For the Biotechnology subindustry, Celyad Oncology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celyad Oncology's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's FCF Margin % falls into.

Celyad Oncology FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Celyad Oncology's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-29.802	/	0
	=	%

Celyad Oncology's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	0	/	0
	=	%

Celyad Oncology FCF Margin % Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Celyad Oncology (Celyad Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (OTCPK:CYADY) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

CYAD:Belgium

Address

Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435

Website

https://www.celyad.com

Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.